https://nova.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:50289 Wed 28 Feb 2024 16:38:42 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:15467 Sat 24 Mar 2018 08:19:03 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:18742 2 years) was associated with poor survival in both groups.Conclusions: FPC represents 9% of PC, and the risk of malignancy in kindred does not appear to be confined to the pancreas. Patients with FPC have more precursor lesions and include fewer active smokers, but other clinicopathologic factors and outcome are similar to those in patients with SPC. Furthermore, some FPC kindreds may exhibit anticipation. A better understanding of the clinical features of PC will facilitate efforts to uncover novel susceptibility genes and the development of early detection strategies.]]> Sat 24 Mar 2018 08:02:49 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:44769 Mon 24 Oct 2022 09:03:39 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:49579 Mon 22 May 2023 11:19:14 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:39992 p < 0.001). Many survivors and parents have unmet needs for genetics-related services and information. Greater access to services and information might allow survivors at high risk for late effects to detect and prevent side effects early and improve medical outcomes. Addressing families’ needs and preferences during survivorship may increase satisfaction with survivorship care.]]> Fri 15 Jul 2022 10:13:46 AEST ]]>